We have demonstrated that serum macrophage migration inhibitory factor (MIF) was significantly elevated in patients with extensive alopecia areata (AA). Recently, functional polymorphisms have been identified in the MIF promoter region. To address the functional and prognostic relevance of the À173G/C and À794[CATT] 5-8 repeat polymorphisms in MIF genes in patients with extensive AA, 113 patients with extensive AA and 194 healthy controls were genotyped. We found that MIFÀ173*C was a risk factor for early onset (o20 years) of extensive AA (odds ratio for GC heterozygotes with À173G/C was 4.88 (95% CI, 2.04-11.8), P ¼ 0.00038; odds ratio for CC homozygotes with À173G/C was 10.42 (95% CI, 2.56-43.5), P ¼ 0.0011). We found no statistically significant differences in the genotype frequencies of the À794[CATT] 5-8 repeat polymorphism and extensive AA. These results suggest that polymorphisms within the MIFÀ173*C allele confer an increased risk of susceptibility to the extensive forms of AA, especially with an early onset of disease. MIF is therefore suggested to be closely implicated in the pathogenesis of the more extensive forms of AA.
Introduction
The pathogenesis of alopecia areata (AA) is still uncertain. The immune system has been implicated in its pathogenesis and certain immunomodulatory cytokines may play an important role in this disease. The contribution of cytokines thought to be involved in the pathogenesis of AA has been well studied. Several lines of clinical and experimental data point toward cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-a, as being crucial inducers of hair loss in AA. The distribution of hair loss in patients with the TNF-a phenotype À308 was different between patients with the patchy form of disease and patients with alopecia totalis (AT) or alopecia universalis (AU) disease. 1 Recently, a strong association was reported between polymorphisms in the IL-1 receptor antagonist gene (IL1RN) at position þ 4734, IL1RN þ 2018 and AA. 2 In these studies, the presence of a genetic heterogeneity was suggested to account for the differences in disease severity and to influence the age of onset of AA.
Macrophage migration inhibitory factor (MIF) was the first lymphokine reported to prevent the random migration of macrophages. 3 A recent finding demonstrated that MIF functions as an initiator of inflammation and the immune response by regulation of a number of proinflammatory cytokines, including TNF-a and IL-1. 4 In human inflammatory diseases, MIF has a regulatory role in acute respiratory distress syndrome, asthma, rheumatoid arthritis and additionally in skin inflammatory diseases, such as atopic dermatitis. 5 Recently, functional polymorphisms have also been identified in the MIF promoter region; single nucleotide polymorphisms (SNPs) at position À173 (G to C) and in a tetranucleotide CATT repeat beginning at nucleotide position À794 have been associated with altered levels of MIF gene transcription in vitro. 6, 7 We previously reported that serum MIF is increased in patients with extensive AA and postulated that MIF might play a key role in the pathogenesis of extensive AA. 8 In the present study, we examined whether MIF gene promoter polymorphisms contribute to the risk of more extensive or early-onset forms of AA.
Results
The distribution of MIFÀ173G/C and À794[CATT] [5] [6] [7] [8] repeat polymorphisms in extensive AA and controls is shown in Table 1 . The genotype distribution for each polymorphism was in Hardy-Weinberg equilibrium in patients with extensive AA as well as in control subjects. None of the MIFÀ173G/C and À794[CATT] 5-8 promoter genotypes were associated with the development of extensive AA patients (Table 2) . We also related these polymorphisms to subgroups of patients with AA stratified by disease severity or age of disease onset. A severity of alopecia tool (SALT) score was used to subdivide the severity of AA, 9 which were AA multiplex (SALT score S 3 and S 4 ) and AT/AU (SALT score S 5 ). We found that the MIFÀ173*C is a risk factor for disease early onset (o20 years); GG homozygotes odds ratio (OR) for GC heterozygotes of the À173G/C polymorphism was 4.88 (95% confidence interval (CI), 2.04-11.8; P ¼ 0.00038) and the OR for CC homozygotes of the À173G/C polymorphism was 10.42 (95% CI, 2.56-43.5; P ¼ 0.0011), calculated using the SYSTAT software ( Table 2 ). Individuals with the GC or CC genotype had significantly higher risk for early age at onset of AA (o20 years); compared with GG homozygotes, odds ratio (OR) for GC genotype (OR, 5.5; 95% CI, 2.35-12.9; P ¼ 0.00009). Compared with the older onset of AA, the GC or CC genotype was also significantly frequent in the younger onset of the disease (OR, 30.3; 95% CI, 7.5-121.8; Po0.00001). In contrast, the À794[CATT] 5-8 repeat polymorphism was associated with none of the AA subgroups (Table 2) .
Analysis using the haplo.em program showed that the À173G/C and À794[CATT] 5-8 promoter polymorphisms were in significant linkage disequilibrium with the À173C allele strongly associated with the 7-CATT repeat allele (the likelihood ratio statistic ¼ 217.8, df ¼ 2, Po0.000001). Haplotype analyses using the haplo.score program for early age at onset of AA (o20 years) revealed that the global score statistic was 64.102 (df ¼ 6, Po0.0001, Global stimulation P ¼ 0.0002, based on 20 000 simulation repetitions) and the empirical P-value for the max-statistic was 0.0024 ( Table 3) . As judged by the haplotype-specific scores, the G/5-CATT haplotype was associated with a lower risk of AA (P ¼ 0.0001). On the other hand, C/5-CATT and C/7-CATT haplotypes were 
Values are number (%). AT: complete loss of all hair on the scalp; AU: complete loss of the entire body hair (SALT score S 5 ); AA multiplex patients can involve more than 50% hair loss of the scalp (SALT score S 3 and S 4 ). associated with an increased risk of AA (P ¼ 0.0019 and 0.0011, respectively) ( Table 3 ). When the frequencies of the C/7-CATT haplotype and the other haplotypes combined were compared, higher frequency of the C/7-CATT haplotype was found in early age at onset of AA than that in controls (w 2 ¼ 5.17, P ¼ 0.023) or in older age at onset of the disease (w 2 ¼ 12.45, P ¼ 0.00042). We then examined luciferase activity using the DualLuciferase Reporter Assay System, and found that transfection of the clone containing the C/7-CATT haplotypes into CEMC7 cells resulted in significantly increased luciferase activity relative to cells containing G/5-CATT haplotype (Po0.001) (Figure 1 ).
Discussion
In the present study, we have demonstrated that MIFÀ173*C is a risk factor for early onset extensive form of AA (o20 years). Furthermore, the MIFÀC/7-CATT haplotype was closely associated with an increased risk of extensive AA in early-onset patients. Transfection of the clone containing the C/7-CATT haplotype into a T-lymphoblast cell line resulted in significantly increased luciferase activity compared to that of G/5-CATT haplotype, supporting these findings. MIF was originally identified as a lymphokine that concentrates macrophages at inflammatory loci, is a potent activator of macrophages in vivo and is considered to play an important role in cell-mediated immunity. 3, 10 Since the molecular cloning of MIF, 11 this cytokine has been reevaluated as a proinflammatory cytokine and pituitaryderived hormone that potentiates endotoxemia. 12, 13 It has been shown that T cells and macrophages secrete MIF in response to various proinflammatory stimuli such as endotoxins. 4 It is evident that the mechanisms of hair follicle dysfunction in AA are immunological and controlled by activated T cells. 14 Hair loss is associated with a perifollicular lymphocytic infiltrate made up primarily of CD4 þ cells, along with a CD8 þ intrafollicular infiltrate. Although the function of these T cells in disease pathogenesis is not fully understood, cytokines released from T cells seem to be important mediators leading to AA hair loss. Proinflammatory cytokines lead to reductions in growth factor secretion by dermal papilla fibroblasts and result in premature catagen stage development, which is characterized by an abnormal pattern of cell degeneration and apoptosis. 15 IL-1 and TNF-a may play a particular role in the AA pathophysiology of inflammatory hair loss. IL-1 has been shown to inhibit hair growth in vitro and may be one of the factors triggering the arrest of hair growth in vivo.
16 TNF-a also inhibits hair follicle growth in vitro. 17 The IL-1 and TNF-a gene polymorphisms have been previously investigated. Galbraith et al 18 found evidence of increased susceptibility to AA with certain IL-1/immunogloblin k lightchain genotypes. The association has been reported between the severity of AA and the inheritance of allele 2 of a five-allele variable number tandem repeat polymorphism in intron 2 of the IL1RN. 19 A stronger association with IL1RN was observed in patients with severe AA and in those with early-onset disease (o20 years).
2 A TNF-a polymorphism was also studied in AA and a significant difference was found in TNF-308 genotype between patients with patchy disease and those with AT/AU. 1 These previous studies strongly suggested the presence of genetic heterogeneity in the more extensive forms of AA.
It was speculated that MIF may be produced by multiple cellular sources in inflammatory and autoimmune diseases such as activated T lymphocytes and monocytes. 20, 21 We have previously demonstrated that serum MIF was elevated in patients with extensive AA, and immunohistochemical MIF staining was positive for perifollicular-infiltrated lymphocytes in telogen hair follicles in patients with extensive AA. 8 On the basis of our results, we speculate that activated T cells might be a potential source of serum MIF. MIF levels may reflect the inflammatory symptoms in extensive AA. The direct pathogenic mechanism of MIF in AA is still unclear. Recently, the growth-inhibiting effects induced on fibroblasts by MIF has been reported. 22 Imbalance between proinflammatory cytokines and cytokine antagonists or inhibitors is one of the factors that may predispose patients to the initiation or perpetuation of autoimmune diseases including AA. It is known that the proinflammatory mediators IL-1 and TNF-a are potent MIF polymorphism in extensive alopecia areata T Shimizu et al inhibitors of hair follicle cell proliferation, with a concomitant inhibition of hair growth. 17 MIF is upregulated by TNF-a, and MIF in turn augments the secretion TNF-a. 4, 23 Therefore, these inflammatory cytokines may be implicated in the induction or continuation of damage to hair follicles, and MIF may play an important part in the pathophysiology of inflammatory hair loss as in AA.
The MIF gene maps to chromosome 22q11.2, and an SNP (G to C transition) in the 5 0 -flanking region at position 173 of the MIF gene is associated with susceptibility to adult inflammatory arthritis. 24 Donn et al 25, 26 initially reported that individuals possessing the C allele had an increased risk of systemic-onset juvenile idiopathic arthritis (JIA), and later, that the MIFÀ173*C-CATT7 haplotype was associated with all JIA independent of subgroup. This polymorphism also has the potential to be associated with an increased expression of MIF via production of an activator protein-4 response element in the MIF promoter. A CATT tetranucleotide repeat element beginning at À794, within the MIF promoter, also appears to play a role in determining susceptibility to rheumatoid arthritis. 26 Recently, both MIFÀ173G/C and À794[CATT] 5-8 repeat polymorphisms in the MIF promoter region have been associated with altered levels of MIF gene transcription, and significant association between the À173G/C and À794[CATT] 5-8 repeat polymorphisms and atopy in a sample of the Japanese population was found. 27 In inflammatory skin diseases, the presence of the MIFÀ173*C polymorphism or the À794[CATT] 5-8 repeat polymorphism was positively correlated with psoriasis in Caucasian patients. 26 Our findings support evidence that polymorphisms in the MIFÀ173*C allele confer an increased risk of susceptibility to the more severe or extensive forms of AA in the Japanese population, especially in early-onset disease subtypes. Since these cytokine-related alleles are clearly associated with AA, our present study further implicates a vital role of MIF in the pathogenesis of AA.
Materials and methods
Patients and controls SALT scores were used to subdivide the severity of AA, and we defined more than 50% hair loss of the scalp (SALT score S 3 -S 5 ) as extensive AA in this study. 9 Peripheral blood samples were obtained, with informed consent, from 113 Japanese patients with extensive AA recruited from dermatology clinics in Hokkaido University, Sapporo, Japan. The age range was 5-76 years (mean 32.2) and included 40 male and 73 female subjects. All subjects gave written, informed consent for enrollment in the study and all associated procedures. The Ethics Committee of the Hokkaido University School of Medicine approved this study. AA multiplex patients can involve more than 50% hair loss of the scalp (SALT score, S 3 and S 4 ). Six ophiasis type AA patients were included in this group. In more severe disease cases, the alopecia can progress to complete loss of all hair on the scalp, AT, or further to cause a complete loss of all body hair, AU (SALT score, S 5 ). Clinical information was updated at follow-up examinations. No family history of extensive AA (SALT score, S 3 -S 5 ) was observed. We also divided the AA patients into two subgroups on the basis of age of disease onset, as previously described. 28 DNA samples from healthy controls were also obtained from 194 consecutive blood samples (aged 18-72 years, mean age 41.6 years; 115 male and 79 female subjects). Concomitant autoimmune diseases including thyroid diseases, and atopic dermatitis patients diagnosed according to the criteria of Hanifin and Rajika 29 were excluded in this study.
Screening for MIF polymorphism
For each individual, we genotyped the À173G/C promoter polymorphisms using the assay that combines kinetic (real-time quantitative) polymerase chain reaction (PCR) with allele-specific amplification in which primers were designed 30 (Primer Express software; PE Applied Biosystems, Foster City, CA, USA) to specifically amplify either the À173G or À173C allele in separate PCRs (À173G forward primer, 5
0 -CCGCCAAGTGGAGAA-CAGG-3 0 ; À173C forward primer, 5 0 -CCGCCAAGTGGA GAACAGC 3 0 ; À173G reverse primer, 5 0 -GGCGCACCG CTCCAAC-3 0 ; À173C reverse primer, 5 0 -GGCGCACCGC TCCAAG-3 0 ). The PCR products were detected using the ABI 7700 Sequence Detection System with a dsDNAspecific fluorescent dye SYBR Green I (PE Applied Biosystems). For typing of the CATT tetranucleotide repeat polymorphism beginning at À794, DNA was amplified by PCR using a carboxyfluorescein-labeled reverse primer (forward primer, 5 0 -TGCAGGAACCAA TACCCATAGG-3 0 ; reverse primer, 5 0 -AATGG TAAACTCGGGGAC-3 0 ). The PCR products were separated by electrophoresis through a performanceoptimized polymer-4 gel using an ABI 310 DNA sequencer (PE Applied Biosystems). For each individual, allele sizes were calculated using the Genescan Analysis computer program (PE Applied Biosystems).
Luciferase reporter gene assay Two plasmids were constructed, corresponding to the three prevalent haplotypes: G/5-CATT and C/7-CATT as previously described. 27 The human T-lymphoblast cell line, CEMC7 cell, was obtained from the Health Science Research Resources Bank (Osaka, Japan). CEMC7 cells (1 Â 10 5 ) were then transfected with 0.1 mg of one of the three constructs and 0.1 mg of pRL-TK vector, an internal control for monitoring transfection efficiency. After 24 h, we measured luciferase activity using the Dual-Luciferase Reporter Assay System (Promega, Tokyo, Japan).
Statistical analysis
The association of MIF promoter polymorphisms was measured using an OR with 95% CI, as estimates of relative risk for development of AA. The À794[CATT] 5-8 genotypes were combined into three categories: 5, 5 genotype; 5, X genotypes; and X, X genotypes (allele X represents any allele other than five repeats of CATT). ORs were adjusted for sex and age. These analyses were conducted using the SYSTAT program (SPSS Inc.). We used the Hardy-Weinberg equilibrium program to compare observed numbers of genotypes with the numbers of genotypes expected under the normal Hardy-Weinberg equilibrium. 31 To evaluate linkage disequilibrium between À173G/C and À794CATT repeat polymorphisms, we used the haplo.em function in the Haplo.Stats program, which calculated the likelihood ratio statistic for linkage equilibrium by estimating haplotype frequencies. Haplotype analysis was conducted using the haplo.score function in the Haplo.Stats program to test statistical association between the MIF haplotypes and AA, which performed adjustment for covariates and computation of simulation P-values for each haplotype. 32 All reporter gene data points were represented as the mean7s.e.m. results of multiple, independent experiments. Differences were tested by the Student's t-test and were considered statistically significant at Po0.05.
